Melatonin: Sleep Timing, Doses, and What the Evidence Shows

Table of contents

• Evidence summary
• What melatonin is
• All forms and types of melatonin
• How melatonin works
• What works and what does not
• Benefits with evidence grades
• Risks and all side effects
• All interactions
• Who should avoid melatonin
• Dosage and how to take it
• Frequently asked questions
• Sources

Evidence summary

Claim	Evidence	Source country	Funding / conflict trace	Strength
Jet lag	10 randomized trials in the Cochrane review; 8 of 10 trials found reduced jet lag when melatonin was taken near destination bedtime, with 0.5–5 mg similarly effective and doses above 5 mg not more effective.	UK / New Zealand review; trial countries varied	Cochrane review; no product sponsor presented in public abstract; older underlying trials vary and some funding details are incompletely reported.	High for short-term adult jet lag (Cochrane)
Chronic primary insomnia	AASM suggests clinicians not use melatonin for adult sleep-onset or sleep-maintenance insomnia; meta-analyses show small sleep-latency improvements but not enough for a strong clinical recommendation.	United States guideline; international trials	AASM guideline disclosed risk of publication bias from drug trials; melatonin recommendation was weak and based on limited evidence.	Low-to-moderate; not first-line (AASM, PLOS One meta-analysis)
Delayed sleep-wake phase disorder	AASM 2015 guideline suggests strategically timed melatonin for adults and youth with delayed sleep-wake phase disorder, but the recommendation is weak and timing matters more than dose.	United States guideline	AASM task force reported no conflicts under AASM policy.	Moderate practical use; weak guideline strength (AASM circadian guideline)
Shift-work sleep	Evidence is inconsistent; some trials show improved daytime sleep, but timing is difficult and alertness/performance benefits are uncertain.	International	Underlying trials vary; systematic reviews note heterogeneity.	Mixed (rapid evidence review, Sleep Foundation)
Supplement label accuracy	US gummy products ranged from 74% to 347% of labeled melatonin; one product had no detectable melatonin.	United States	JAMA authors disclosed Consumers Union/Pew support for one author and FDA/NIH/USDA grants for another; no melatonin manufacturer funding reported.	Strong quality concern (JAMA)
Long-term pediatric safety	Long-term puberty effects remain uncertain; one Dutch follow-up did not find substantial deviation in puberty scores, while a clinician review found no experimental trials designed to test pubertal timing.	Netherlands / Canada	Follow-up and review were academic; pediatric reviews note limited evidence and uncertainty.	Insufficient for routine long-term use (Dutch follow-up, puberty review)

Independent evidence and credibility scorecard

Source	Country	Evidence type	Funding / conflicts	Independence rating	Credibility rank	Likely motivation
Cochrane jet-lag review	UK / international	Systematic review of RCTs	No melatonin-company funding stated in public record; older trials have incomplete funding detail.	Probably independent	Strong	Maintain systematic-review credibility through transparent methods.
AASM circadian guideline	United States	Clinical practice guideline using GRADE	Task-force conflicts checked under AASM policy; none declared in the guideline.	Independent	Very strong	Professional guideline accuracy and clinical reputation.
AASM insomnia guideline	United States	Clinical practice guideline	Guideline notes many pharmacologic trials have industry-funding/publication-bias risk; melatonin recommendation is weak.	Independent guideline, with trial-base limitations	Strong	Standardize sleep-medicine prescribing.
JAMA melatonin gummy analysis	United States	Analytical chemistry study	Author disclosures include consumer-protection and government research support; one conference received support from supplement-related companies, but no product sponsor funded the test.	Probably independent	Strong	Consumer safety and label-accuracy accountability.
IR sublingual spray vs PR tablet pharmacokinetic study	France	Open-label randomized crossover PK study, n=14 men	Funded by PiLeJe Laboratoire; several authors were employees, and one author consulted for PiLeJe, Biocodex, and Sanofi.	Conflicted	Moderate for pharmacokinetic pattern only	Product-development evidence; useful for form behavior but not for efficacy superiority.
Melatonin vs sertraline tinnitus trial	Iran	Randomized clinical trial, n=70	Funded by Isfahan University of Medical Sciences; authors reported no conflicts.	Probably independent	Moderate	Academic clinical research; limited by active-comparator design and no placebo arm.
COVID-19 RCT meta-analysis	Taiwan	Meta-analysis of 3 RCTs	Authors declared no conflicts; funding statement not clearly visible in the public full text.	Probably independent but underpowered evidence base	Moderate	Rapid evidence synthesis during pandemic; evidence remains small.

What melatonin is

Melatonin is a hormone made primarily by the pineal gland in darkness, and light suppresses its secretion; under a typical schedule, secretion begins in the early evening and peaks around 3–4 a.m. (CDC Yellow Book). Supplemental melatonin is therefore best understood as a chronobiotic—an input that can shift body-clock timing—and only secondarily as a mild sedating sleep aid (AASM circadian guideline).

The active compound — what actually does the work

The active compound is N-acetyl-5-methoxytryptamine, usually listed simply as melatonin. It acts mainly through melatonin MT1 and MT2 receptors that help signal biological night, shift circadian phase, and influence sleep propensity; the same molecule is present whether it is synthesized industrially or extracted from biological material (StatPearls/NCBI Bookshelf).

All forms and grades

Form / type	What it is	Best fit	Main advantage	Main downside	Verdict
Immediate-release tablet/capsule	Standard oral melatonin designed to release quickly after swallowing.	Jet lag, sleep-onset timing, delayed sleep phase, RBD protocols that specify immediate-release.	Matches evidence where a short peak matters; Cochrane found slow-release 2 mg less useful for jet lag than fast-release timing.	May wear off before early-morning awakenings; supplement label accuracy varies.	Best default for circadian timing (Cochrane, AASM RBD guideline).
Extended-release / prolonged-release	Tablet designed to release melatonin through the night, such as 2 mg prolonged-release prescription products in some countries.	Sleep-maintenance complaints in older adults when prescribed; not ideal for rapid jet-lag shifting.	More sustained levels may fit nighttime maintenance; NHS notes 2 mg slow-release tablets as the usual UK medicine form for insomnia.	Less suitable when a short peak is needed; crushing or splitting can destroy the release profile.	Useful for selected sleep-maintenance use, not best for jet lag (NHS dosing, Circadin dissolution study).
Sublingual spray/tablet	Melatonin held under the tongue or sprayed in the mouth for faster absorption.	People needing a fast onset and who can dose precisely.	A 2023 crossover PK study found an immediate-release sublingual spray peaked faster and higher than a prolonged-release tablet.	The PK study was company-funded and involved only 14 healthy men, so efficacy superiority is not proven.	Promising for fast absorption; evidence grade limited (PK study).
Gummies	Chewable candy-like melatonin products, often marketed for sleep and relaxation.	Adults who cannot swallow tablets, if product quality is verified and dose is low.	Convenient and palatable.	Highest practical concern for children and label mismatch; US gummies tested at 74–347% of label, and one had no detectable melatonin.	Convenient but quality-risk form (JAMA, NCCIH).
Synthetic melatonin	Laboratory-made melatonin, usually from chemical synthesis.	Most modern supplements and medicines.	Molecularly identical to human melatonin and avoids animal-tissue contamination risk.	Quality depends on manufacturer testing, excipients, and regulatory category.	Preferred source type when independently tested.
Natural animal-derived pineal melatonin	Historically extracted from bovine, sheep, or pig pineal glands.	Generally no good consumer use-case.	“Natural” label appeal only.	Animal-tissue products carry theoretical viral/prion/protein contamination concerns; modern industrial use has shifted away from this source.	Avoid (review on sources, microorganism/plant review).

How it works

What the body does with it

Oral melatonin is absorbed, undergoes first-pass liver metabolism, and is metabolized largely through CYP1A2 with contribution from CYP2C19; this explains why fluvoxamine and estrogens can raise melatonin exposure (European Circadin product information). The circadian effect depends on timing: evening/early biological night dosing can advance the clock earlier, while morning dosing can delay it later, so taking it at the wrong time can worsen misalignment (CDC Yellow Book).

Why form and delivery matter

Immediate-release products create a short signal that is useful for circadian shifting, while prolonged-release products are intended to maintain levels through the night; Cochrane’s jet-lag review specifically noted that 2 mg slow-release melatonin was relatively ineffective for jet lag, suggesting the short-lived peak matters for that use (Cochrane). Sublingual forms may peak faster than oral prolonged-release tablets, but the best available head-to-head PK study was sponsored by a product manufacturer and did not prove better clinical sleep outcomes (PK study).

What works and what does not

Claimed benefit	Verdict	Evidence	Key caveat
Sleep onset for jet lag	WORKS	Cochrane found 8 of 10 trials reduced jet lag when 0.5–5 mg was taken close to target bedtime at destination.	Timing is decisive; wrong-time dosing can delay adaptation (Cochrane, CDC).
Sleep onset for delayed sleep phase	WORKS	AASM suggests strategically timed melatonin for adults and children/adolescents with DSWPD.	Guideline strength is weak; light control and consistent schedule are part of treatment (AASM).
Sleep onset for primary chronic insomnia	MIXED	Meta-analysis shows small improvements; AASM recommends against melatonin for adult chronic insomnia.	CBT-I and insomnia diagnosis matter; do not use as a substitute for insomnia care (AASM, PLOS One).
Sleep onset for shift work	MIXED	Some studies suggest easier daytime sleep, but reviews emphasize timing difficulty and uncertain alertness benefits.	Night-shift schedules vary; wrong light exposure can overpower the dose (Sleep Foundation).
General sleep quality	MIXED	Primary sleep-disorder meta-analysis found improvements in sleep latency, total sleep time, and sleep quality, but effects are modest and heterogeneous.	Small average changes may not be meaningful for every person (PLOS One meta-analysis).
REM sleep behavior disorder in Parkinson’s disease	MIXED	AASM conditionally suggests immediate-release melatonin for isolated and secondary RBD, and conditionally recommends rivastigmine for Parkinson’s-related secondary RBD.	No RBD drug has a strong recommendation; evidence for prolonged-release melatonin was insufficient (AASM RBD guideline).
Tinnitus	INSUFFICIENT EVIDENCE	Small trials suggest possible THI or sleep-related improvement, including one Iran RCT vs sertraline.	Not enough independent placebo-controlled evidence to treat tinnitus itself; benefit may reflect better sleep (tinnitus trial).
Cancer adjuvant	INSUFFICIENT EVIDENCE	NCCIH says studies for cancer symptoms or treatment side effects have been small and mixed.	Do not replace or delay cancer treatment; oncology team must review interactions (NCCIH).
Cluster headache prevention	MIXED	A 20-person Italian pilot RCT found 10 mg reduced attack frequency in episodic cluster headache; a 9-person adjunctive pilot did not find benefit.	Small studies; cluster headache needs neurologist-directed treatment (Leone trial, adjunctive pilot).
COVID-19 treatment or prevention	INSUFFICIENT EVIDENCE	A 2022 meta-analysis included only 3 RCTs and found signals that need confirmation.	Not a replacement for vaccination, antivirals, oxygen, or standard COVID care (COVID meta-analysis, NCCIH).

Benefits by claim

- Grade A — Jet lag: Timed immediate-release melatonin can reduce jet-lag symptoms in adults crossing multiple time zones, especially eastward travel and five or more time zones (Cochrane). - Grade B — Delayed sleep-wake phase disorder: Strategically timed melatonin can help shift sleep earlier, but timing, light management, and a stable schedule matter more than simply raising the dose (AASM, Sleep Foundation delayed sleep phase). - Grade C — Primary insomnia / general sleep quality: Meta-analyses show modest sleep-latency and sleep-quality signals, but AASM still recommends against melatonin for adult chronic insomnia because clinical certainty and effect size are limited (PLOS One, AASM). - Grade C — REM sleep behavior disorder: Immediate-release melatonin is conditionally recommended by AASM, including secondary RBD, but all recommendations are conditional and Parkinson’s-related RBD may require specialist-directed alternatives (AASM RBD guideline). - Grade D — Tinnitus, cancer adjuvant, COVID: Current evidence is too small, mixed, or indirect for routine claims (NCCIH, COVID meta-analysis, tinnitus trial).

Risks and all side effects

Short-term melatonin appears safe for most adults, but long-term safety is not well established, and NCCIH specifically notes that long-term safety information is lacking (NCCIH). In UK patient guidance, most people have no side effects, common listed effects include daytime sleepiness/tiredness, headache, stomach ache, nausea, dizziness, irritability/restlessness, dry mouth or skin, limb pains, strange dreams, and night sweats; serious effects such as depression symptoms, fainting/vertigo, vision changes, unexplained bleeding/bruising, and anaphylaxis are rare and need urgent advice (NHS side effects).

Side effect / concern	Frequency	Dose relationship	Practical note	Source
Daytime drowsiness / reduced alertness	Commonly reported	More likely with higher doses, late-night dosing, prolonged-release forms, older age, sedatives, or CYP1A2 inhibitors	Do not drive or use machinery if affected; Mayo advises avoiding driving or machinery within 5 hours.	Mayo Clinic, NHS
Headache	Commonly reported	May increase with higher dose or poor timing	Reduce dose or stop if persistent.	NHS
Dizziness	Commonly reported	More relevant with antihypertensives, alcohol, and older age	Sit/lie down; avoid alcohol.	NHS
Nausea / stomach pain	Commonly reported	May be worse with higher doses or taking without food for some products	NHS suggests taking tablets or liquid after food if nausea occurs.	NHS
Vivid dreams / strange dreams / night sweats	Reported; NHS lists strange dreams as a common side-effect topic	Often dose- and REM-sleep related in practice; lower dose may help	Stop or reduce dose if disruptive.	NHS, Mayo Clinic
Long-term safety	Unknown	Higher nightly doses and years-long use raise more unanswered questions	Use the shortest duration that solves the timing problem; review chronic use.	NCCIH
Natural melatonin production / dependence	No clear evidence of classic dependence, but long-term rhythm effects are under-studied	More concern with chronic high-dose use	Melatonin is not a habit-forming sedative in the benzodiazepine sense, but nightly use should still be reviewed.	Sleep Foundation, chronic administration review
Pediatric endocrine/puberty concerns	Uncertain	Concern grows with long duration, prepubertal use, and unsupervised dosing	A clinician review found no experimental trials designed to test pubertal timing; use children’s melatonin only with clinician supervision.	puberty review, pediatric recommendation

Pediatric safety: the cautious read

Melatonin may be appropriate for certain children with diagnosed sleep or neurodevelopmental conditions, but it should not be used to force an otherwise healthy child to sleep earlier, and caregivers should consult a clinician before use (Sleep Foundation, NCCIH). A 2023 evidence-based pediatric recommendation concluded that benefits in otherwise healthy children and adolescents with idiopathic chronic insomnia are limited, unwanted events are likely, and melatonin should never be first choice before sleep hygiene and non-pharmacologic interventions (eClinicalMedicine pediatric review).

All interactions

Interacts with	Examples to name	Severity	Mechanism	Action
Anticoagulants / antiplatelets	Warfarin, aspirin, clopidogrel, heparin, enoxaparin, apixaban, rivaroxaban, dabigatran	High caution	Possible additive bleeding risk; Cochrane notes case reports suggesting harm in warfarin users, and NHS lists warfarin as a medicine to check before melatonin.	Do not start without prescriber input; warfarin users need INR monitoring and bleeding surveillance.
Warfarin specifically	Warfarin / Coumadin	High caution	Narrow therapeutic index plus possible anticoagulant/platelet effects and case reports.	Avoid unsupervised use; monitor INR and bruising/bleeding.
Immunosuppressants	Tacrolimus, cyclosporine, corticosteroids, biologics, post-transplant regimens	Avoid unless specialist approves	Melatonin may stimulate immune function and interfere with immunosuppressive therapy.	Transplant and autoimmune patients should not self-start.
Sedatives / benzodiazepines / CNS depressants	Diazepam, temazepam, clonazepam, alprazolam, zolpidem, zopiclone, zaleplon, opioids, alcohol, sedating antihistamines	High caution	Additive sedation, impaired reaction time, falls, confusion, and next-day drowsiness.	Avoid combining unless prescribed; no alcohol with melatonin.
Antidepressants	Fluvoxamine, amitriptyline, imipramine, nortriptyline, SSRIs/SNRIs	Moderate to high; avoid fluvoxamine combination	Fluvoxamine inhibits CYP1A2/CYP2C19 and the Circadin label reports 17-fold higher AUC and 12-fold higher Cmax; sedating antidepressants add drowsiness.	Avoid fluvoxamine + melatonin; discuss SSRI/SNRI or tricyclic combinations with prescriber.
Blood pressure drugs	Beta-blockers, ACE inhibitors, ARBs, clonidine, calcium-channel blockers	Moderate caution	Melatonin may affect blood pressure; some antihypertensives may add dizziness/hypotension, while nifedipine may be antagonized.	Monitor BP; use low dose only with clinician guidance.
Nifedipine specifically	Nifedipine GITS / Procardia-type calcium-channel blocker	Avoid or specialist-monitor	A double-blind crossover study in hypertensive patients controlled on nifedipine found evening 5 mg melatonin worsened 24-hour blood pressure control.	Avoid self-use if taking nifedipine; ask prescriber.
Diabetes medications	Insulin, sulfonylureas, metformin, GLP-1 drugs, SGLT2 inhibitors	Moderate caution	Melatonin may affect glucose regulation; Mayo flags diabetes medications as an interaction category.	Monitor glucose when starting/stopping; avoid high-dose unsupervised use.
Contraceptives / estrogens	Ethinyl estradiol combinations, hormonal contraceptives, HRT	Moderate caution	Estrogens can inhibit melatonin metabolism; Circadin labeling says estrogens increase melatonin levels, and Mayo notes additive sedative effects.	Start low; watch next-day drowsiness.
Anticonvulsants / seizure-threshold drugs	Carbamazepine, valproate, levetiracetam; seizure-threshold-lowering medicines	Moderate to high in epilepsy	NCCIH says people with epilepsy need medical supervision; Mayo warns melatonin might inhibit anticonvulsants and increase seizure frequency in vulnerable children.	Use only under clinician supervision.
CYP1A2/CYP2C19 inhibitors or inducers	Fluvoxamine, cimetidine, quinolones, rifampicin, carbamazepine, caffeine	Moderate caution	Metabolism can be increased or decreased, changing melatonin exposure and drowsiness.	Check pharmacist before combining.

Interaction sources: NHS, Mayo Clinic, European Circadin product information, nifedipine crossover study, and Cochrane jet-lag review.

Who should avoid melatonin

Avoid self-prescribing melatonin if you are pregnant or breastfeeding, have epilepsy, have an autoimmune disease, have dementia, have a bleeding disorder, take warfarin or other blood thinners, take immunosuppressants, take sedatives, use nifedipine, or are giving it to a child without clinician supervision (NCCIH, Mayo Clinic, NHS interactions). Older adults may remain sedated longer, and AASM/NCCIH caution against melatonin use in people with dementia because of adverse-event concerns (NCCIH).

Dosage and how to take it

The safest practical rule is: start low, time it to the biological goal, and stop when the timing problem is solved. CDC notes that 0.5–1 mg is often enough for circadian shifting and advises against high-dose melatonin above 5 mg for jet lag because excess melatonin may remain present at the wrong clock time (CDC Yellow Book).

Goal	Typical adult starting range	Timing	Preferred form	Notes
Jet lag	0.5–3 mg; up to 5 mg used in trials	Destination bedtime, often 10 p.m.–midnight, for a few nights	Immediate-release	Do not take early in the day; 0.5–5 mg similarly effective in Cochrane.
Delayed sleep-wake phase	0.3–1 mg is a conservative start; studies/guidelines vary	Several hours before current natural sleep onset or per sleep specialist plan	Immediate-release	Light exposure and evening light avoidance are part of the treatment.
Occasional sleep-onset difficulty	0.3–1 mg to start	30–60 minutes before desired bedtime if using for sleepiness	Immediate-release	If insomnia persists, evaluate cause rather than escalating dose.
Sleep maintenance in older adults	Prescription directions vary; UK commonly uses 2 mg slow-release	1–2 hours before bed, or per product label	Prolonged-release	Do not crush slow-release tablets; specialist review for longer courses.
RBD under specialist care	AASM notes starting 3 mg and increasing by 3 mg increments up to 15 mg for secondary RBD	Bedtime	Immediate-release	Specialist-directed; bedroom safety measures remain essential.

Related research

For deeper, evidence-graded context on the conditions melatonin is most often used for, see Pure City Research's condition guides: - Sleep: prevention and management guide

Frequently Asked Questions

Is melatonin safe to take every night?

Short-term use appears safe for most adults, but long-term safety data are limited, so nightly use should be reviewed if it continues beyond a short course (NCCIH). If insomnia persists, melatonin may be masking a treatable sleep disorder, medication effect, anxiety/depression pattern, caffeine issue, or circadian problem.

What is the best dose of melatonin for sleep?

For circadian shifting, CDC notes that 0.5–1 mg is often sufficient, and Sleep Foundation advises starting with the lowest dose because doses below 1 mg may work as well as higher doses for some people (CDC, Sleep Foundation). For jet lag, Cochrane found 0.5–5 mg similarly effective, with doses above 5 mg not more effective (Cochrane).

Is 10 mg melatonin too much?

A 10 mg dose is not automatically toxic, but it is often more than needed for ordinary sleep-onset or jet-lag use and may raise the risk of next-day drowsiness, vivid dreams, dizziness, and mistimed circadian effects. CDC specifically advises against high-dose melatonin above 5 mg for jet lag because excess melatonin can remain present at the wrong time of day (CDC).

Does melatonin stop my body from making its own melatonin?

There is no strong clinical evidence that short-term, low-dose melatonin permanently shuts down natural production, but long-term nightly use is still insufficiently studied and may disturb rhythm timing if used at the wrong time (chronic administration review). The safer framing is not “dependence,” but “clock training”: use the lowest effective dose at the correct time and reassess.

Can children take melatonin?

Children should take melatonin only with clinician guidance, especially because pediatric long-term endocrine and puberty effects are not fully answered and gummies can be mislabeled or accidentally ingested (NCCIH, puberty review, JAMA). A 2023 pediatric recommendation says melatonin should never be the first choice for otherwise healthy children/adolescents with idiopathic chronic insomnia (eClinicalMedicine).

Which is better: immediate-release or extended-release melatonin?

Immediate-release is usually better when the goal is a circadian signal such as jet lag, delayed sleep phase, or AASM RBD protocols; prolonged-release is more logical for selected sleep-maintenance use and older-adult prescription settings (Cochrane, AASM RBD guideline, NHS dosing). Do not crush prolonged-release tablets because it can change the release profile (Circadin dissolution study).

Are melatonin gummies reliable?

Not always. A JAMA analysis of US melatonin gummies found actual melatonin ranged from 74% to 347% of the label amount, and one product had no detectable melatonin (JAMA). If using gummies, choose a low dose, keep them away from children, and prefer products with independent quality verification.

Can I take melatonin with antidepressants or birth control?

Do not combine melatonin with fluvoxamine unless a prescriber explicitly approves, because European product information reports fluvoxamine can raise melatonin exposure dramatically through CYP1A2/CYP2C19 inhibition (European Circadin product information). Estrogen-containing contraceptives can also increase melatonin levels and side effects, so start low and ask a pharmacist or clinician (Mayo Clinic, NHS interactions).

Sources

1. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews. Cochrane
2. Centers for Disease Control and Prevention. Jet Lag Disorder. CDC Yellow Book. CDC
3. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults. PubMed
4. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. AASM clinical practice guideline for intrinsic circadian rhythm sleep-wake disorders. PMC
5. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: Melatonin for the Treatment of Primary Sleep Disorders. PMC
6. Crawford C, et al. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment. PMC
7. Howell M, et al. Management of REM sleep behavior disorder: an AASM clinical practice guideline. PMC
8. National Center for Complementary and Integrative Health. Melatonin: What You Need To Know. NCCIH
9. NHS. Side effects of melatonin. NHS
10. NHS. Taking melatonin with other medicines and herbal supplements. NHS
11. NHS. How and when to take melatonin. NHS
12. Mayo Clinic. Melatonin. Mayo Clinic
13. Avula B, et al. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. PMC
14. Grigg-Damberger MM, Ianakieva D. Poor Quality Control of Over-the-Counter Melatonin. PMC
15. Claustrat B, et al. Bioavailability of melatonin after prolonged-release tablet and immediate-release sublingual spray. PMC
16. Chua HM, et al. Dissolution of Intact, Divided and Crushed Circadin Tablets. PMC
17. Piazza E, Lusardi P, Fogari R. Cardiovascular effects of melatonin in hypertensive patients controlled by nifedipine. PMC
18. European Commission. Circadin product information. European Commission PDF
19. Leone M, et al. Melatonin versus placebo in prophylaxis of cluster headache. PubMed
20. Pringsheim T, et al. Melatonin as adjunctive therapy in cluster headache prophylaxis. PubMed
21. Nilforoush M, et al. Comparison of Melatonin and Sertraline Therapies on Tinnitus. PMC
22. Chao CM, et al. Efficacy of melatonin in COVID-19: systematic review and meta-analysis of RCTs. PMC
23. van Geijlswijk IM, et al. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment. PMC
24. Boafo A, et al. Could long-term administration of melatonin to prepubertal children affect timing of puberty? PMC
25. Ussing A, et al. Melatonin in children/adolescents with idiopathic chronic insomnia: systematic review and recommendation. PMC
26. Sleep Foundation. Melatonin: Usage, Side Effects, and Safety. Sleep Foundation
27. Sleep Foundation. Delayed Sleep Phase Disorder. Sleep Foundation
28. Food Safety and Standards Authority of India. Direction on health supplements and nutraceuticals.
29. Reiter/Rozencwaig-related review on melatonin sources and “natural”/synthetic claims. PMC
30. Melatonin from microorganisms, algae, and plants review. PMC